PL217628B1 - Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy - Google Patents

Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy

Info

Publication number
PL217628B1
PL217628B1 PL377557A PL37755703A PL217628B1 PL 217628 B1 PL217628 B1 PL 217628B1 PL 377557 A PL377557 A PL 377557A PL 37755703 A PL37755703 A PL 37755703A PL 217628 B1 PL217628 B1 PL 217628B1
Authority
PL
Poland
Prior art keywords
resveratrol
virus
cells
infection
viral
Prior art date
Application number
PL377557A
Other languages
English (en)
Polish (pl)
Other versions
PL377557A1 (pl
Inventor
Enrico Garaci
Anna Teresa Palamara
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PL377557A1 publication Critical patent/PL377557A1/pl
Publication of PL217628B1 publication Critical patent/PL217628B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377557A 2002-11-06 2003-10-14 Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy PL217628B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000562A ITRM20020562A1 (it) 2002-11-06 2002-11-06 Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.

Publications (2)

Publication Number Publication Date
PL377557A1 PL377557A1 (pl) 2006-02-06
PL217628B1 true PL217628B1 (pl) 2014-08-29

Family

ID=32310188

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377557A PL217628B1 (pl) 2002-11-06 2003-10-14 Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy

Country Status (18)

Country Link
US (1) US8431617B2 (https=)
EP (1) EP1567137B1 (https=)
JP (1) JP4589118B2 (https=)
KR (1) KR101060331B1 (https=)
AR (1) AR041891A1 (https=)
AT (1) ATE381929T1 (https=)
AU (1) AU2003279551A1 (https=)
CA (1) CA2504872C (https=)
CY (1) CY1107302T1 (https=)
DE (1) DE60318327T2 (https=)
DK (1) DK1567137T3 (https=)
ES (1) ES2295660T3 (https=)
IT (1) ITRM20020562A1 (https=)
MX (1) MXPA05004628A (https=)
PL (1) PL217628B1 (https=)
PT (1) PT1567137E (https=)
TW (1) TWI337863B (https=)
WO (1) WO2004041260A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951285A2 (en) * 2005-11-18 2008-08-06 Ares Trading S.A. Interferon in influenza
EP2268272A2 (en) * 2008-03-06 2011-01-05 Mount Sinai School of Medicine of New York University Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
WO2010053949A1 (en) * 2008-11-04 2010-05-14 Metaproteomics, Llc Phytochemical compositions and methods for activating amp-kinase
US20110236349A1 (en) * 2008-12-19 2011-09-29 Koff Jonathan L Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
KR100950445B1 (ko) 2009-10-26 2010-04-02 주식회사 중앙백신연구소 감초로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
WO2011150413A1 (en) 2010-05-28 2011-12-01 Mount Sinai School Of Medicine Antiviral compounds and uses thereof
CA2850597A1 (en) * 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
EP2952209B1 (en) 2014-06-04 2018-03-28 Alfasigma S.p.A. Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
EP2952180B1 (en) 2014-06-04 2017-01-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
EP3120842A1 (en) * 2015-07-20 2017-01-25 Opterion Health AG Peritoneal therapeutic fluid
KR20170039456A (ko) 2015-10-01 2017-04-11 동아대학교 산학협력단 오동나무로부터 추출한 ｃ-제라닐플라보노이드계 물질을 포함하는 인플루엔자 예방 및 치료용 약학 조성물
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
CN108893558B (zh) * 2018-05-24 2022-04-05 江苏海宏制药有限公司 一种桑木液原液抗病毒实验方法以及装置
EP4132277B1 (en) * 2020-04-05 2025-11-26 Mong, Michael Systems and methods for treating coronavirus
WO2026044308A1 (en) 2024-08-26 2026-03-05 Medizinische Universität Wien Treatment and prevention of diseases caused by influenza virus with 3,3',4,4',5,5'-hexahydroxy-trans-stilbene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2778337B1 (fr) 1998-05-05 2001-08-31 Inst Nat Sante Rech Med Antagonistes des ligands du recepteur des arylhydrocarbures
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
DE60015568D1 (de) * 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür

Also Published As

Publication number Publication date
JP2006507295A (ja) 2006-03-02
TW200501935A (en) 2005-01-16
TWI337863B (en) 2011-03-01
JP4589118B2 (ja) 2010-12-01
KR20050071627A (ko) 2005-07-07
US20050239906A1 (en) 2005-10-27
CA2504872C (en) 2011-07-05
AR041891A1 (es) 2005-06-01
CY1107302T1 (el) 2012-11-21
AU2003279551A1 (en) 2004-06-07
US8431617B2 (en) 2013-04-30
EP1567137A1 (en) 2005-08-31
ATE381929T1 (de) 2008-01-15
PT1567137E (pt) 2008-02-19
DE60318327T2 (de) 2008-12-18
CA2504872A1 (en) 2004-05-21
ES2295660T3 (es) 2008-04-16
PL377557A1 (pl) 2006-02-06
WO2004041260A1 (en) 2004-05-21
EP1567137B1 (en) 2007-12-26
ITRM20020562A1 (it) 2004-05-07
DE60318327D1 (de) 2008-02-07
MXPA05004628A (es) 2005-09-08
DK1567137T3 (da) 2008-04-28
KR101060331B1 (ko) 2011-08-30

Similar Documents

Publication Publication Date Title
Amatore et al. Influenza virus replication in lung epithelial cells depends on redox‐sensitive pathways activated by NOX4‐derived ROS
RU2769317C2 (ru) Способы лечения гриппа
PL217628B1 (pl) Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy
AU2020321880B2 (en) Antioxidant and antiviral compositions and methods
CN112316152B (zh) 经酸酐修饰的蛋白质抑制冠状病毒的方法
WO2016069854A1 (en) Enhancing the anti-tumor, anti-viral, and anti-protozoan effects of 2-amino-n-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl] phenyl]acetamide (osu-03012) and other pharmaceutical drugs
US20140121237A1 (en) Methods for Inhibiting Virus Replication
JP2023123440A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
Stelitano et al. Antiviral activity of nitazoxanide against Morbillivirus infections
WO2017083971A1 (en) Compositions and methods for treatment of influenza
Mebratu et al. Bik mediates caspase-dependent cleavage of viral proteins to promote influenza A virus infection
WO2019023181A1 (en) METHODS OF TREATING INFLUENZA-RELATED VIRAL PNEUMONIA
Zhao et al. A broad-spectrum virus-and host-targeting antiviral peptide against SARS-CoV-2 and other respiratory viruses
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
Alalem et al. A novel mechanistic study on inhibiting influenza A virus replication by a newly extracted polypeptide targeting host autophagy
Kirkpatrick et al. Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against viral infections. mBio 9: e00696-18
KR20210144288A (ko) 매스틱 검을 유효성분으로 함유하는 항바이러스 조성물
JP5173813B2 (ja) インフルエンザの予防および処置のための薬剤
US20220401554A1 (en) Use of membrane inhibitors to enhance vaccine development against enveloped viruses
RU2695336C1 (ru) Композиция на основе пептида, подавляющего репликацию вируса гриппа А
Schwarzer-Sperber et al. The Bovine Seminal Plasma Protein PDC-109 Possesses Pan-Antiviral Activity
Corne et al. ATF4 Signaling in HIV-1 Infection: Viral Subversion of a Stress Response Transcription Factor. Biology 2024, 13, 146. htps
JP2024516712A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の治療のためのクロロフィル誘導体の使用
RU2302236C2 (ru) Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics